A study published in The New England Journal of Medicine reported the effects of canagliflozin therapy on cardiovascular and renal outcomes. The study included participants with type 2 diabetes and high cardiovascular risk. The results demonstrated that the rate of the primary outcome (composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) was lower with canagliflozin than with placebo (26.9 vs. 31.5 participants per 1,000 patient-years). In addition, a possible benefit of canagliflozin was seen with regard to the progression of albuminuria and the composite outcome of a sustained 40% decrease in the estimated glomerular filtration rate, need for renal-replacement therapy, or death due to renal causes. It was also mentioned that treatment with canagliflozin was accompanied by a lower risk of cardiovascular events in contrast to placebo.